These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes. Galsky MD; Small AC; Tsao CK; Oh WK CA Cancer J Clin; 2012; 62(5):299-308. PubMed ID: 22535487 [TBL] [Abstract][Full Text] [Related]
23. Cabozantinib for the treatment of renal cell carcinoma. Escudier B; Lougheed JC; Albiges L Expert Opin Pharmacother; 2016 Dec; 17(18):2499-2504. PubMed ID: 27835047 [TBL] [Abstract][Full Text] [Related]
24. Cabozantinib in Thyroid Cancer. Fallahi P; Ferrari SM; Di Bari F; Materazzi G; Benvenga S; Miccoli P; Antonelli A Recent Pat Anticancer Drug Discov; 2015; 10(3):259-69. PubMed ID: 26152149 [TBL] [Abstract][Full Text] [Related]
26. Cabozantinib Unlocks Efficient Chaudagar KK; Landon-Brace N; Solanki A; Hieromnimon HM; Hegermiller E; Li W; Shao Y; Joseph J; Wilkins DJ; Bynoe KM; Li XL; Clohessy JG; Ullas S; Karp JM; Patnaik A Mol Cancer Ther; 2021 Feb; 20(2):438-449. PubMed ID: 33277441 [TBL] [Abstract][Full Text] [Related]
27. Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti-Prostate Cancer Activity. Wang X; Huang Y; Christie A; Bowden M; Lee GS; Kantoff PW; Sweeney CJ Clin Cancer Res; 2015 Dec; 21(24):5578-87. PubMed ID: 26289068 [TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946 [TBL] [Abstract][Full Text] [Related]
29. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. Nguyen HM; Ruppender N; Zhang X; Brown LG; Gross TS; Morrissey C; Gulati R; Vessella RL; Schimmoller F; Aftab DT; Corey E PLoS One; 2013; 8(10):e78881. PubMed ID: 24205338 [TBL] [Abstract][Full Text] [Related]
30. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130 [TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma. Liao W; Huang J; Hutton D; Zhu G; Wu Q; Wen F; Bai L; Li Q Liver Int; 2019 Dec; 39(12):2408-2416. PubMed ID: 31544330 [TBL] [Abstract][Full Text] [Related]
32. Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer. Qiao Y; Feng FY; Wang Y; Cao X; Han S; Wilder-Romans K; Navone NM; Logothetis C; Taichman RS; Keller ET; Palapattu GS; Alva AS; Smith DC; Tomlins SA; Chinnaiyan AM; Morgan TM Neoplasia; 2016 Jan; 18(1):1-9. PubMed ID: 26806347 [TBL] [Abstract][Full Text] [Related]
33. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461 [TBL] [Abstract][Full Text] [Related]
34. Cabozantinib: A Review in Advanced Hepatocellular Carcinoma. Deeks ED Target Oncol; 2019 Feb; 14(1):107-113. PubMed ID: 30767164 [TBL] [Abstract][Full Text] [Related]
35. Hand-foot skin reaction with primarily dorsal involvement in a patient with metastatic renal cell carcinoma on cabozantinib. Goyal A; Jacobsen AA; O'Leary D; Watson A; Luikart S; Gaddis KJ Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941722 [TBL] [Abstract][Full Text] [Related]
37. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062 [TBL] [Abstract][Full Text] [Related]
38. Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. Heidenreich A; Chowdhury S; Klotz L; Siemens DR; Villers A; Ivanescu C; Holmstrom S; Baron B; Wang F; Lin P; Shore ND Eur Urol; 2017 Apr; 71(4):534-542. PubMed ID: 27497762 [TBL] [Abstract][Full Text] [Related]
39. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Grüllich C Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794 [TBL] [Abstract][Full Text] [Related]
40. A novel multiple tyrosine-kinase targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple solid tumors: cabozantinib. Roy S; Narang BK; Rastogi SK; Rawal RK Anticancer Agents Med Chem; 2015; 15(1):37-47. PubMed ID: 25181996 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]